Introduction
============

The World Health Organization statistics indicated that \~2 million people suffer pain everyday worldwide. Pain is one of the most common symptoms in patients with malignant tumor, substantially affecting patients' quality of life. Approximately 25% of newly diagnosed patients report pain and \~60%--80% of patients with advanced cancer have chronic pain, one-third of them are categorized as severe.[@b1-ppa-10-571],[@b2-ppa-10-571] Lung cancer is the most common malignant tumor worldwide,[@b3-ppa-10-571] with an average survival of \<1 year in advanced patients making palliative care an especially important consideration. The incidence of pain is 47% in all patients with lung cancer, and 76% in those in palliative care.[@b4-ppa-10-571]

Although most patients achieve adequate pain control, those with more complex pain syndromes require intense and complex analgesic schedules.[@b5-ppa-10-571] Pain intensity is a key element of prognostication and management of cancer pain,[@b6-ppa-10-571]--[@b8-ppa-10-571] and greater awareness of the prognostic factors associated with poor pain control would guide specific and appropriate treatment strategies. The Edmonton Classification System for Cancer Pain has been extensively studied[@b5-ppa-10-571],[@b7-ppa-10-571],[@b9-ppa-10-571] and indicates that incident pain (breakthrough pain), neuropathic pain, psychological distress, addiction, and cognitive function are predictors of pain control.[@b6-ppa-10-571],[@b7-ppa-10-571],[@b9-ppa-10-571] However, there is no consensus generally on the prognostic factors for pain control or specifically on the pain characteristics in patients with lung cancer having moderate or severe chronic pain. Therefore, this study analyzed pain characteristics and prognostic data from 152 patients with lung cancer having moderate or severe chronic pain at the Cancer Center in the Bethune First Hospital of Jilin University, People's Republic of China, between January 1, 2012, and May 31, 2013.

Methods
=======

This retrospective study was approved by ethics committee of the First Hospital of Jilin University. Data including host characteristics (sex and age), disease factors (pathological type, tumor--node--metastasis \[TNM\] stage, and presence of bone metastases), pain factors (pain intensity, locations, causes, mechanisms, breakthrough pain, and its frequency), treatment (final opioid doses, drug ladder, medication route, and combination with nonsteroidal anti-inflammatory drugs \[NSAIDs\]), and the Karnofsky Performance Status (KPS) were analyzed from 152 patients with pathologically diagnosed lung cancer reporting moderate or severe chronic pain at the Cancer Center of The First Hospital of Jilin University, People's Republic of China, between January 1, 2012, and May 31, 2013. Pain control was evaluated after 3 days of analgesia in all the patients. For the patients medicated with potent opioids, the final median opioid doses were transformed into morphine equivalent daily dose (MEDD) prior to analysis, while for those using weak opioids, the doses were not transformed.

All patients were treated in accordance with the National Comprehensive Cancer Network (NCCN) cancer pain guidelines for adults.[@b10-ppa-10-571] Patients rated their pain intensity daily using the Numeric Rating Scale, ranging from 0 (no pain) to 10 (worst possible pain) with ratings of 1--3 corresponding to mild pain, 4--6 moderate pain, and 7--10 severe pain. For the purpose of this study, stable pain control was defined as a Numeric Rating Scale rating of ≤3/10 or patients receiving \<3 breakthrough analgesic doses/d.

Univariate and multivariate logistic regression analyses using SPSS 17.0 (SPSS Inc., Chicago, IL, USA) were used to identify the associations between the variables and the pain control after 3 days of analgesia. As the sample distribution was not normal, nonparametric Kruskal--Wallis and Mann--Whitney tests examined differences in pain intensity and final median opioid doses. The chi-square test was used to compare the frequency data. Statistical significance was set at *P*\<0.05 (two tailed).

Results
=======

The demographic and clinical characteristics of the 152 patients included in the study are listed in [Table 1](#t1-ppa-10-571){ref-type="table"}. The male/female ratio was 1.87:1, and age ranged from 32 to 81 years, with a median age of 58 years. There were 65 patients (42.8%) older than 60 years and 87 (57.2%) younger than 60 years. Non-small-cell lung cancer accounted for 132 (86.8%) cases and 20 (13.2%) were small-cell lung cancer. A total of 26 patients (17.1%) were in stage I, II, or III; 112 patients (73.7%) were in stage IV; and the stage was unknown for 14 patients (9.2%). Bone metastases were apparent in 67 patients (44.1%). Most patients exhibited moderate pain (72.4%), with the remainder (27.6%) classified as having severe pain. The majority of patients reported chest or back pain (76.3%), while pain in other parts accounted for just 23.7%. The main cause of pain was tumor invasion (92.1%), 71 patients (46.7%) had neuropathic pain and 39 patients (25.7%) had frequent breakthrough pain (more than three times per day).

The associations between the pain intensity and the variables of sex, age, pathological type, TNM stage, bone metastases, locations, causes, mechanisms of pain, and frequent breakthrough pain are shown in [Table 2](#t2-ppa-10-571){ref-type="table"}. The frequent breakthrough pain was associated with high pain intensity (*P*\<0.001), while the other eight variables were not significantly associated with pain intensity (*P*\>0.05).

All 152 patients accepted analgesic treatment, and 124 (81.6%) achieved adequate pain control after 3 days but pain control was poor in 28 (18.4%). As shown in [Table 1](#t1-ppa-10-571){ref-type="table"}, weak opioids were used by 69 patients (45.4%) and 83 (54.6%) used potent opioids. There were 147 patients (96.7%) taking analgesics by oral administration, two (1.3%) by injection, and three (2.0%) by transdermal patches. Furthermore, 45 patients (29.6%) were taking NSAIDs in addition to opioids. More patients reported a KPS ≥80 after 3 days of analgesic treatment (*P*\<0.001) ([Table 3](#t3-ppa-10-571){ref-type="table"}).

The associations between the pain control after 3 days of analgesic treatment and the ten variables are summarized in [Table 4](#t4-ppa-10-571){ref-type="table"}. Both univariate and multivariate logistic regression analyses showed that bone metastases (univariate: odds ratio \[OR\] =3.343, 95% confidence interval \[CI\]: 1.398--7.991, *P*=0.007; multivariate: OR =3.583, 95% CI: 1.136--11.297, *P*=0.029), severe pain (univariate: OR =4.415, 95% CI: 1.760--9.761, *P*=0.001; multivariate: OR =3.878, 95% CI: 1.510--9.960, *P*=0.005), and frequent breakthrough pain (univariate: OR =3.267, 95% CI: 1.383--7.715, *P*=0.007; multivariate: OR =2.798, 95% CI: 1.033--7.576, *P*=0.043) were significantly associated with poor pain control. Sex, age, pathological type, TNM stage, locations of pain, causes, and mechanisms of pain were not significantly associated with pain control (*P*\>0.05).

The final opioid doses of the 83 patients using potent opioids were transformed into MEDD prior to analysis. The associations between the final MEDD and the ten variables are shown in [Table 5](#t5-ppa-10-571){ref-type="table"}. Significantly higher opioid doses were used in patients with severe pain (*P*=0.015), neuropathic pain (*P*=0.020), and frequent breakthrough pain (*P*=0.016); however, there were no significant differences in final MEDD in patients of different sex, age, pathological type, TNM stage, locations, and causes of pain or in patients with or without bone metastases (*P*\>0.05).

As shown in [Table 6](#t6-ppa-10-571){ref-type="table"}, opioids combined with NSAIDs achieved better pain control after 3 days of analgesic treatment than opioids without NSAIDs (*P*=0.001).

Discussion
==========

Chronic cancer pain seriously affects patients' quality of life, and pain control remains one of the main treatment obstacles. Lung cancer has the highest incidence of all malignancies and is commonly associated with pain. Since the average survival of patients with advanced lung cancer is \<1 year, analgesia can have a significant impact on the quality of life. Characterizing the aspects of pain associated with lung cancer and the prognostic factors associated with pain management would provide valuable guidance for clinical analgesic treatment. However, there is currently no consensus on these parameters, and the evidence-based studies published to date are insufficient to draw firm conclusions. This study retrospectively analyzed the pain characteristics of 152 patients with lung cancer having moderate or severe chronic cancer pain and identified factors that may predict the outcome of analgesic treatment and could be used to inform clinical decision making.

Patient demographic statistics indicate that the number of male patients with lung cancer is approximately twice the number of female patients. Although the peak age for lung cancer diagnosis is 60--79 years old, in our study, elderly patients (aged 60 years or older) with moderate or severe pain reported it less frequently than the younger patients (aged \<60 years) (42.8% vs 57.2%). This may be due to the different tolerances to pain in patients of different ages, which is supported by Gagliese et al,[@b11-ppa-10-571] who found that young patients were more sensitive to pain.[@b11-ppa-10-571] Additionally, younger patients may be less tolerant of pain, impacting on their quality of life, while elderly patients may think pain is an inevitable part of cancer, and thus bear that pain untreated over time. Differences in pain perception between these two groups may lead to differences in pain intensity and different treatment outcomes.

In this study, approximately three-quarters of the patients were with advanced lung cancer, which is in accordance with foreign study.[@b4-ppa-10-571] Non-small-cell lung cancer accounted for 86.8% of the cases, which is concordant with its known high incidence. Patients with moderate pain accounted for 72.4% of the total, and those with severe pain accounted for 27.6%. In approximately three-quarters of patients, the location of pain was the chest or back, with other parts accounting for approximately one-quarter. In most patients, the pain was caused by tumor invasion and metastases (92.1%), while their pain was due to other causes in a small proportion of cases. Approximately half of the patients had bone metastases, approximately half had neuropathic pain, and approximately one-quarter reported frequent breakthrough pain.

This study showed that high pain intensity was associated with frequent breakthrough pain, which is in line with previous studies.[@b12-ppa-10-571] Thus, reducing the frequency of breakthrough pain may lower the mean pain intensity, giving better pain management. In this study, we did not detect any associations between the pain intensity and the other variables.

After priority was given to opioid analgesia for 3 days, 81.6% of patients achieved adequate pain control, and more patients reported a KPS ≥80, suggesting analgesia can improve patients' quality of life. Most patients (54.6%) were given potent opioids, mainly by the oral route (96.7%), which is consistent with the NCCN guidelines.[@b10-ppa-10-571]

In this study, logistic regression analysis showed that severe pain, frequent breakthrough pain, and presence of bone metastases were independent risk factors for poor pain control after 3 days of analgesic treatment. Additionally, analysis of patients using potent opioids showed that high final opioid doses were associated with severe pain, neuropathic pain, and frequent breakthrough pain. Therefore, these factors may lead to difficulty in managing pain and poor pain control. Similar to previous studies,[@b7-ppa-10-571],[@b9-ppa-10-571] patients with more complex pain syndromes such as neuropathic and breakthrough pain, of moderate or severe pain intensity, may require complex analgesic strategies to achieve adequate pain control. Factors that may influence the outcome of pain management include host factors (eg, age, sex, and genetics), disease factors (eg, cancer type and stage), pain factors (eg, intensity, causes, and mechanisms), and among others.[@b13-ppa-10-571] In this study, sex, age, pathological type, TNM stage, locations, and causes of pain were not significantly associated with pain control.

Pain intensity plays a key role in the assessment and management of cancer pain, it not only guides clinical decision making but it is also an important prognostic factor for predicting complex pain.[@b6-ppa-10-571],[@b14-ppa-10-571] Fainsinger et al[@b7-ppa-10-571] published an international multicenter study showing that higher pain intensity was associated with greater time taken to achieve stable pain control, as well as more adjuvant therapy, and higher final opioid doses. Kaasa et al[@b8-ppa-10-571] summarized previous research results and pointed out that severe pain was more complex and refractory than moderate pain.

Breakthrough pain is considered to be a transient exacerbation of pain that occurs either spontaneously or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain.[@b15-ppa-10-571] Most patients with cancer pain (63%) suffer from breakthrough pain, which is usually severe pain, and several studies have recognized this breakthrough pain as refractory pain.[@b7-ppa-10-571],[@b13-ppa-10-571] Fainsinger et al[@b7-ppa-10-571] showed that median final opioid dose required to achieve stable pain control in patients with breakthrough pain was 60 mg, while it was 32 mg in patients without breakthrough pain. In that study, breakthrough pain was also associated with greater time and more adjuvant therapy to reach stable pain control.

Neuropathic pain is due to peripheral or central nervous system injury, leading to pain nerve fibers or pain centers producing abnormal nerve impulses. Previous studies have regarded neuropathic pain as a refractory pain index.[@b7-ppa-10-571],[@b8-ppa-10-571] In a study by Fainsinger et al,[@b7-ppa-10-571] the median final opioid dose required to achieve stable pain control in patients with nociceptive pain was 30 mg, while it was 100 mg in patients with neuropathic pain. Coadministration of tricyclic antidepressants and anticonvulsants can assist in the management of neuropathic pain. For intractable neuropathic pain, interventional therapies such as nerve blocks or nerve radiofrequency ablation can be effective treatments.

Bone metastases pain (hereafter referred to as bone pain) often has characteristics associated with inflammatory pain and neuropathic pain, and it is more complex than other kinds of pain, so opioids alone often do not provide sufficient analgesia.[@b16-ppa-10-571] In animal experiments, three to ten times the opioid dose required to treat inflammatory pain was required to alleviate bone pain.[@b17-ppa-10-571] In addition, bone metastases are the main cause of somatic breakthrough pain, and the latter is refractory. Analgesia combined with radiotherapy and bisphosphonate can effectively alleviate bone pain.[@b18-ppa-10-571]

Combining opioids with NSAIDs led to better pain control in 29.6% patients on this treatment protocol. This is consistent with Mercadante and Giarratano's study[@b19-ppa-10-571] that analyzed studies published from 2001 to 2011 investigating NSAIDs combined with opioids and concluded that combining NSAIDs with opioids can facilitate better and more rapid control of pain.

There are other relevant prognostic factors for pain management in patients with lung cancer having moderate or severe chronic pain, such as genetic factors, psychological factors, and among others. Genetic studies suggest that single-nucleotide polymorphisms in the opioid receptor gene,[@b20-ppa-10-571],[@b21-ppa-10-571] catecholamine-*O*-methyltransferase polymorphisms,[@b22-ppa-10-571] and the activity of cytochrome P450 enzymes[@b23-ppa-10-571] can affect the outcome of analgesic treatment. Psychological distress can also hinder effective analgesic treatment, extending the time required to achieve stable pain control and necessitating more adjuvant treatment and drugs to control pain.[@b7-ppa-10-571],[@b9-ppa-10-571] With regard to studies investigating prognostic factors for pain management in patients with lung cancer pain, we need to increase sample sizes, extend observing times, refine the clinical data, and include more potential prognostic factors in the analysis, in order to obtain more significant data and provide a better basis for clinical practice.

This study provides important data that highlight some prognostic factor for poor pain management that should be taken into consideration when planning analgesia.
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###### 

Patients' demographics and clinical characteristics (N=152)

  Characteristics                N=152 (%)
  ------------------------------ ------------
  **Demographics**               
  Sex                            
   Male                          99 (65.1)
   Female                        53 (34.9)
  Age, median, range (years)     58, 32--81
   \<60                          87 (57.2)
   ≥60                           65 (42.8)
  **Clinical characteristics**   
  Pathological type              
   Non-small-cell                132 (86.8)
   Small cell                    20 (13.2)
  Pain intensity                 
   Moderate                      110 (72.4)
   Severe                        42 (27.6)
  TNM stage                      
   I/II/III                      26 (17.1)
   IV                            112 (73.7)
   Unknown                       14 (9.2)
  Causes of pain                 
   Nontumor invasion             12 (7.9)
   Tumor invasion                140 (92.1)
  Bone metastases                
   Without                       85 (55.9)
   With                          67 (44.1)
  Locations of pain              
   Chest or back                 116 (76.3)
   Other parts                   36 (23.7)
  Frequent breakthrough pain     
   Without                       113 (74.3)
   With                          39 (25.7)
  Neuropathic pain               
   Without                       81 (53.3)
   With                          71 (46.7)
  **Analgesic treatment**        
  Drug ladder                    
   Weak opioids                  69 (45.4)
   Strong opioids                83 (54.6)
  Combined with NSAIDs           
   Without                       107 (70.4)
   With                          45 (29.6)
  Route of administration        
   Oral                          147 (96.7)
   Injection                     2 (1.3)
   Patch                         3 (2.0)
  Pain control                   
   Good                          124 (81.6)
   Poor                          28 (18.4)

**Abbreviations:** NSAIDs, nonsteroidal anti-inflammatory drugs; TNM, tumor--node--metastasis.

###### 

Comparison on pain intensity stratified by demographics and clinical characteristics (N=152)

  Characteristics              NRS score, median (IQR)   *P*-value[a](#tfn2-ppa-10-571){ref-type="table-fn"}
  ---------------------------- ------------------------- -----------------------------------------------------
  Sex                                                    0.574
   Male                        6 (4--7)                  
   Female                      6 (5--6)                  
  Age                                                    0.698
   \<60 years                  6 (4--7)                  
   ≥60 years                   6 (5--7)                  
  Pathological type                                      0.955
   Non-small-cell              6 (5--7)                  
   Small cell                  6 (4--7)                  
  Bone metastases                                        0.406
   Without                     6 (4--7)                  
   With                        6 (5--7)                  
  Causes of pain                                         0.063
   Nontumor invasion           5 (4--6)                  
   Tumor invasion              6 (5--7)                  
  Neuropathic pain                                       0.144
   Without                     6 (4--7)                  
   With                        6 (5--7)                  
  Locations of pain                                      0.500
   Chest or back               6 (4--7)                  
   Other parts                 6 (5--7)                  
  Frequent breakthrough pain                             \<0.001
   Without                     5 (4--6)                  
   With                        6 (6--8)                  
  TNM stage                                              0.664
   I/II/III                    6 (4--7)                  
   IV                          6 (5--7)                  
   Unknown                     5 (4--6)                  

**Note:**

The Mann--Whitney test was used for comparisons of two groups, and the Kruskal--Wallis test was used for comparisons of more than two groups.

**Abbreviations:** NRS, Numerical Rating Scale; IQR, interquartile range; TNM, tumor--node--metastasis.

###### 

Comparison of KPS before and after analgesic treatment (N=152)

  KPS before treatment   KPS after treatment   Total (%)   *P*-value[a](#tfn4-ppa-10-571){ref-type="table-fn"}   
  ---------------------- --------------------- ----------- ----------------------------------------------------- ---------
  ≥80                    98                    3           101 (66.4)                                            \<0.001
  \<80                   16                    35          51 (33.6)                                             
  Total (%)              114 (75.0)            38 (25.0)   152 (100)                                             

**Note:**

McNemar's test.

**Abbreviation:** KPS, Karnofsky Performance Status.

###### 

Odd ratios of pain poor control after analgesic treatment (N=152)

  Variables                    Univariate              Multivariate                           
  ---------------------------- ----------------------- -------------- ----------------------- -------
  Sex                                                                                         
   Female vs male              0.702 (0.286--1.724)    0.440          0.667 (0.246--1.809)    0.426
  Age                                                                                         
   ≥60 years vs \<60 years     1.005 (0.439--2.301)    0.991          0.984 (0.388--2.492)    0.973
  Pathological type                                                                           
   Small vs non-small-cell     1.125 (0.345--3.667)    0.845          1.594 (0.418--6.084)    0.495
  TNM stage                                                                                   
   IV vs I/II/III              2.091 (0.578--7.558)    0.261          1.033 (0.185--5.759)    0.971
   Unknown vs I/II/III         0.590 (0.056--6.266)    0.661          0.592 (0.044--7.997)    0.693
  Bone metastases                                                                             
   With vs without             3.343 (1.398--7.991)    0.007          3.583 (1.136--11.297)   0.029
  Pain intensity                                                                              
   Severe vs moderate          4.415 (1.760--9.761)    0.001          3.878 (1.510--9.960)    0.005
  Locations of pain                                                                           
   Other vs chest or back      2.094 (0.864--5.077)    0.102          1.012 (0.332--3.080)    0.984
  Tumor invasion                                                                              
   Yes vs no                   2.628 (0.325--21.244)   0.365          0.769 (0.067--8.845)    0.833
  Neuropathic pain                                                                            
   With vs without             1.673 (0.731--3.829)    0.223          1.339 (0.503--3.564)    0.558
  Frequent breakthrough pain                                                                  
   With vs without             3.267 (1.383--7.715)    0.007          2.798 (1.033--7.576)    0.043

**Note:**

Logistic regression analyses were performed.

**Abbreviations:** OR, odds ratio; TNM, tumor--node--metastasis; CI, confidence interval.

###### 

Comparison on final MEDD of patients using strong opioids stratified by demographics and clinical characteristics (n=83)

  Characteristics              MEDD           
  ---------------------------- -------------- -------
  Sex                                         0.534
   Male                        60 (40--80)    
   Female                      80 (40--80)    
  Age                                         0.566
   \<60 years                  60 (40--80)    
   ≥60 years                   60 (40--80)    
  Pathological type                           0.217
   Non-small-cell              60 (40--80)    
   Small cell                  60 (40--80)    
  Bone metastases                             0.413
   Without                     60 (40--80)    
   With                        80 (40--80)    
  Causes of pain                              0.990
   Nontumor invasion           80 (20--80)    
   Tumor invasion              60 (40--80)    
  Neuropathic pain                            0.020
   Without                     60 (20--80)    
   With                        80 (60--80)    
  Pain intensity                              0.015
   Moderate                    60 (40--80)    
   Severe                      80 (50--120)   
  Locations of pain                           0.486
   Chest or back               60 (40--80)    
   Other parts                 80 (40--80)    
  Frequent breakthrough pain                  0.016
   Without                     60 (40--80)    
   With                        80 (45--120)   
  TNM stage                                   0.621
   I/II/III                    60 (40--80)    
   IV                          65 (40--80)    
   Unknown                     50 (20--80)    

**Note:**

The Mann--Whitney test was used for comparisons of two groups, and the Kruskal--Wallis test was used for comparisons of more than two groups.

**Abbreviations:** MEDD, morphine equivalent daily dose; IQR, interquartile range; TNM, tumor--node--metastasis.

###### 

Pain control of patients with opioids combined with NSAIDs or opioids only (N=152)

  Combined with NSAIDs   Pain control   *P*-value[a](#tfn10-ppa-10-571){ref-type="table-fn"}   
  ---------------------- -------------- ------------------------------------------------------ -------
  Yes                    44             1                                                      
  No                     80             27                                                     0.001

**Note:**

Chi-square test.

**Abbreviation:** NSAIDs, nonsteroidal anti-inflammatory drugs.
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